Scinai Immunotherapeutics
SCNI
7 hedge funds and large institutions have $271K invested in Scinai Immunotherapeutics in 2019 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 4 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
36% less funds holding
Funds holding: 11 → 7 (-4)
88% less capital invested
Capital invested by funds: $2.27M → $271K (-$1.99M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$1.28K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVH
Psagot Value Holdings
Tel Aviv,
Israel
|
-$59K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BHB
1
Bank Hapoalim BM
Tel Aviv,
Israel
| $144K | – | – | – |
|
2
HighTower Advisors
Chicago,
Illinois
| $97K | – | – | – |
|
|
LTFS
3
Ladenburg Thalmann Financial Services
Miami,
Florida
| $14K | – | – | – |
|
4
Royal Bank of Canada
Toronto,
Ontario, Canada
| $5K | – | – | – |
|
5
Wells Fargo
San Francisco,
California
| $5K | – | – | – |
|
|
6
Morgan Stanley
New York
| $4K | +$1.28K | +2 | +40% |
|
|
II
7
Ibex Investors
Denver,
Colorado
| $2.07K | – | – | – |
|
|
PVH
8
Psagot Value Holdings
Tel Aviv,
Israel
| – | -$59K | -109 | Closed |
|
|
9
UBS Group
Zurich,
Switzerland
| – | -$5K | -9 | Closed |
|
SCNI Hedge Fund Activity: Q2 2019 in Review
7 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q2 2019, worth a combined $271K — down 88% from $2.27M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of SCNI and 0 opened new positions — a net loss of 4 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was Morgan Stanley, adding an estimated $1.28K. The largest seller was Psagot Value Holdings, exiting entirely with an estimated $59K sold.
- 7 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q2 2019, down from 11 in Q1 2019.
- Funds reported $271K of Scinai Immunotherapeutics stock for Q2 2019, down 88% quarter-over-quarter.
- 0 funds opened new Scinai Immunotherapeutics positions in Q2 2019 and 4 closed out, a net change of -4 holders.
- The largest Scinai Immunotherapeutics buyer in Q2 2019 was Morgan Stanley, an estimated $1.28K added.
- The largest Scinai Immunotherapeutics seller in Q2 2019 was Psagot Value Holdings, an estimated $59K sold.
Based on aggregated 13F filings for Q2 2019.